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This study investigates the effects of mistletoe lectin-I (ML-I) on melanoma growth and spread in vivo. The human melanoma cell line
MV3 was xenografted into severe combined immunodeficient mice and vehicle solution or purified ML-I was administered at 30, 150
and 500ng per kg body weight (20 mice per group) daily. After 19 days, mice were killed, primary tumours (PTs) and lungs were
dissected out, and tumour weights, number of lung metastases (LMs), number of tumour-infiltrating dendritic cells (DCs), and
apoptosis rates in the melanoma cells and in the DCs were assessed. A 35% reduction of PT weight (P¼0.03) and a 55% decrease in
number of LMs (P¼0.016) were evident for low-dose ML-I (30ngkg
 1) treatment but not for higher doses. Mistletoe lectin-I
increased apoptosis rates in the melanoma cells of PTs at all doses, while no induction of apoptosis was noted in the LMs. Low-dose
ML-I significantly increased the number of DCs infiltrating the PTs (Po0.0001) and protected DCs against apoptosis, while higher
doses induced apoptosis in the DCs (Po0.01). Our results demonstrate that low-dose ML-I reduced melanoma growth and number
of metastases in vivo, primarily due to immunomodulatory effects.
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Despite intensive research, no curative treatment exists for
malignant melanoma once it has spread to distant sites (Eigentler
et al, 2003). Conventional chemotherapy or combination of radio-
and chemotherapy have been disappointingly ineffective and have
not led to any considerable prolongation of survival. The hope to
improve survival expectations for melanoma patients thanks to
immunotherapies has either not yet been fulfilled (Edler, 2004).
Thus, it is not astonishing that about 40% of tumour patients turn
to alternative treatment options such as aqueous mistletoe
extracts. In Germany, more than 30 million Euro are spent yearly
with increasing tendency (Steuer-Vogt et al, 2001). However, there
are considerable discrepancies between this widespread usage and
the few numbers of clinically controlled trials on the effect of
mistletoe extracts in cancer therapy, which, moreover, report
controversial results (Kienle et al, 2003; Edler, 2004). One obvious
explanation is that the precise mode of action of aqueous mistletoe
extracts is still unclear. The main therapeutic components of
mistletoe extracts are the three mistletoe lectins (MLs) ML-I, -II,
-III (Bu ¨ssing et al, 1996). However, mistletoe extracts contain
further numerous low molecular weight compounds such as
viscotoxins, polysaccharides, amino acids and phenols, which
might show additional or even reverse biological effects on tumour
cells (Beuth, 1997). Hence, the effect of purified MLs on melanoma
cells in general and on disseminated ones in particular is of
considerable clinical interest.
Of the three MLs, ML-I is the best investigated and consists of an
A-chain having a strong cytotoxic effect due to its ribosome-
inactivating properties (Rip type II) and a B-chain carrying the
carbohydrate-binding site (Barbieri et al, 1993; Langer et al, 1996).
A prerequisite for the internalisation and the cytotoxic activity of
ML-I is its binding to the target cell surface mediated through the
lectin binding domain of the B-chain. As both metastatic primary
malignant melanomas and their metastases express particularly
high numbers of ML-I binding sites, malignant melanoma cells
represent an ideal target for ML-I cytotoxic therapy (Thies et al,
2001, 2007a). Previous in vitro experiments have already demon-
strated a highly significant antiproliferative effect of ML-I on
malignant melanoma cells, which is due to the induction of
apoptosis (Thies et al, 2005). In addition to its cytotoxic effect,
ML-I might have further impact on tumour growth and
metastases through its stimulation of the immune system, raising
the number and the activity of NK cells, dendritic cells (DCs) and
granulocytes (Hajto et al, 1997; Pryme et al, 2006). Furthermore,
antiangiogenic effects have been described for the Korean ML-I
(Park et al, 2001).
However, before purified ML-I can be applied in humans,
extensive preclinical analyses have to be performed. We have
already established a clinically relevant human melanoma
xenograft scid mouse model, in which the effects of drugs on
melanoma growth and spread can be analysed (Thies et al, 2007b).
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sThe first aim of this study is to analyse the potential therapeutic
effects of purified ML-I on melanoma cell growth and spread
in our established human melanoma xenograft scid mouse
model. The second aim is to analyse the mechanisms responsible
for ML-I effects on melanoma in vivo by assessing apoptosis
rates, the number of infiltrating DCs, and vascular counts in
primary melanomas and their spontaneous lung metastases (LMs).
MATERIALS AND METHODS
Cell culture
The human melanoma cell line MV3 was established from a
metastatic melanoma lymph node (Edward, 2001). This cell line
has shown both a 100% subcutaneous tumour engraftment and a
100% spontaneous LM rate within 20 days, when engrafted into
scid mice (Thies et al, 2007b).
MV3 cells were cultured under standard cell culture conditions
(371C, 100% relative humidity, 5% CO2) in RPMI medium (Gibco,
Paisley, Scotland), supplemented with 10% heat-inactivated fetal
bovine serum (Gibco), 2mML -glutamine (Gibco), 100Uml
 1
penicillin and 100mlml
 1 streptomycin (Gibco). The cells were
tested for the presence of mycoplasma using the PCR-based
VenorGeM Mycoplasma Detection Kit (Minerva Biolabs GmbH,
Berlin, Germany). For injection, mycoplasma-free melanoma cells
were harvested by trypsinisation, tested for viability (viabili-
ty495%) and were adjusted to a concentration of 5 10
6 viable
cells per 1ml medium.
ML-I
Mistletoe lectin-I was isolated from leaves of the European
mistletoe (Viscum album) harvested from poplar (40%), apple
tree (30%) and red oak (30%) between November and February.
Purification was performed using affinity chromatography according
to Eifler et al (1994). The ML-I stock solution contained 963mg
ML-I per ml of solution, and about 1% ML-III and less than 0.5%
ML-II.
To avoid erroneous dosage of ML-I through surface adsorption
effects (Cleland et al, 1993), polysterol tubes (Greiner,
Frickenhausen, Germany) were used for the preparation of the
different ML-I dilution series and glass pistons were used for injection.
Animals
The methodology for carrying out the experiment was consistent
with the UKCCCR guidelines for the welfare of animals in
experimental neoplasia (Workman et al, 1997). The experiment
was supervised by the institutional animal welfare officer and
approved by the local licensing authority (Beho ¨rde fu ¨r Soziales,
Gesundheit, Familie, Verbraucherschutz; Amt fu ¨r Gesundheit und
Verbraucherschutz, Hamburg, Germany, project no. F1 8/01).
Pathogen-free male balb/c severe combined immunodeficient
scid/scid mice aged 9–14 weeks were housed in filter top cages and
were provided with sterile water and food ad libitum. All
manipulations were carried out aseptically inside a laminar flow
hood. Before injection of the melanoma cells, mice were weighted
and grouped (adjusted to a mean body weight of 20g (range:
18.5–21.0g) into three treatment groups and one control group
(20 mice per group). One million MV3 cells (in 200ml medium)
were injected subcutaneously between the scapulae of each scid
mouse. Mice received intraperitoneal injections of 200ml PBS
containing 30, 150 or 500ng ML-I per kg of body weight once daily
for next 19 days. Control mice were treated the same way, receiving
vehicle solution only.
Vitality score
All mice were inspected daily and the overall clinical condition,
including appearance, posture, behaviour and physiological
responses, as well as food and water intake, was assessed. Each
position was rated from 1 to 3 points, resulting in a maximum of
12 points for animals with no vital detraction.
Histology
On day 20, the mice were killed by cervical dislocation. The
tumours were excised within their capsule, weighed and immedi-
ately fixed in 4% neutrally buffered formalin. The lungs of all
animals were dissected out en bloc, and fixed in 4% neutrally
buffered formalin for 48h. Thereafter, the lungs were cut under a
dissecting microscope into 1mm-thick slices, which were spread
randomly over a glass slide and then embedded in 4% warm
liquefied agar. Slices were pressed down gently with a glass piston
to avoid floating of the slices within the agar during cooling. The
solidified agar blocks were then routinely processed for wax
histology and were serially sectioned. The number of LMs was
analysed using the simplified quantitative method standardised in
our laboratory as described by Jojovic and Schumacher (2000).
Briefly, every tenth section of each lung was retained (the total
number of sections per lung was evaluated), and 10 sections from
the middle of the block were stained with H&E, and the number of
LMs was counted under 100 magnification field. The mean
numbers of LMs in the 10 sections for each lung (mean value10)
were calculated. This mean value10 minus 20% was multiplied by
the total number of serial sections of the respective lung in order to
estimate the total number of LMs. Furthermore, the size (tumour
cells per metastasis) and the anatomical site of LMs (intravasal vs
extravasal; pulmonary artery, bronchial vessels, intraseptal tissue)
were recorded.
BSA-I histochemistry
For evaluation of the number of tumour-infiltrating DCs, paraffin
sections (5mm) were processed for BSA-I histochemistry (Honda
et al, 1989; Thiele et al, 2000) using an avidin–biotin alkaline
phosphatase staining technique as has been reported previously
(Thies et al, 2001). Briefly, trypsinised tissue sections were
incubated with 10mgml
 1 biotinylated BSA-I (Sigma, Steinheim,
Germany) followed by an incubation with an avidin–alkaline
phosphatase complex (Vectastain, Vector, ABC kit, Burlingame,
CA, USA). Enzyme reactivity of the complex was visualised using
naphthol-AS-bisphosphate as a substrate, and hexatozised New
Fuchsin was used for simultaneous coupling. Negative controls
were treated the same way preincubating BSA-I with its nominal
sugar a-D-galactose. The number of DCs was taken as the mean of
the DC count in five high-power fields (magnification  400) in
slides of PTs and LMs of each mouse.
Apoptotic rates and dimension of ulceration
Apoptotic rates were determined on H&E-stained sections of
primary tumours (PTs) and LMs of each animal, as described by
Kerr et al (1972), who have set the most secure and exact methods,
when diverse methodological approaches to analyse apoptotic
rates are compared (Hall, 1999). Apoptotic rate was taken as the
mean of the apoptotic count in four high-power fields (magnifica-
tion  400) in the vital tumour area of each PT and of each LM.
Apoptotic rates within the tumour-infiltrating DCs were
determined in BSA-I-stained slides, counterstained with H&E,
according to the same criteria described above.
The dimension of ulcerations in the PTs was evaluated
microscopically according to the morphologic criteria described
by Kerr et al (1972) in H&E-stained sections of PTs and measured
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Collagen type IV immunohistochemistry
For antigen retrieval, slides were treated with 0.04% protease XXIV
(Sigma). Nonspecific binding was blocked by 10% normal rabbit
serum. This was followed by an overnight incubation with the
1:200 diluted goat anti-collagen type IV antibody. Then, sections
were incubated with biotinylated rabbit anti-goat antibody for
40min, followed by an incubation with an avidin–alkaline
phosphatase complex (Vectastain, Vector). Enzyme reactivity of
the alkaline phosphatase was visualised as described above.
Negative controls were treated the same way except replacing the
primary antibody by the isotype-matched IgG. The number of
tumour-infiltrating vessels per 0.5mm
2 was assessed as mean of
vascular counts in five fields of view adjusted to 0.5mm
2 in vital
tumour tissue.
Statistical analyses
For all variables, one-way ANOVA tests followed by a Tukey test
were performed to ascertain statistical differences between the
different treatment groups, using Graph Pad Prism Version 4
(Intuitive Software for Science, San Diego, CA, USA). Po0.05 was
considered statistically significant. Graphs show mean and SEM.
Furthermore, correlation analyses between tumour weights,
number of LMs, dimension of necrotic tumour areas and vascular
counts in the different treatment groups were performed using the
Spearman rank correlation. Again, Po0.05 was considered
statistically significant.
RESULTS
Tolerability of ML-I treatment
Tumour growth and ML-I treatment at all three doses had no
negative effect on vitality, behaviour and physiological responses,
appearance or food and water habits of any of the animals. All
animals reached vitality scores of 11–12 out of 12 during and at
the end of the experiment. At necropsy, no treatment-related
lesions could be observed.
Primary tumours
The mean tumour weight in the control group (PBS-only) was
1.96±0.23g, compared to 1.27±0.23, 1.9±0.2 and 1.5±0.18g in
the 30, 150 and 500ngkg
 1 group, respectively. The statistical
analyses showed a significant reduction of the mean tumour
weight in the group treated with 30ngkg
 1 compared to the
control group (P¼0.03), while mean tumour weights of the groups
treated with 150 or 500ngkg
 1 did not significantly differ from
that of the control group (P40.05; Figure 1A). Mean tumour
weights of mice treated with 150ng ML-I per kg body weight were
significantly higher than those of the mice treated with low-dose
ML-I (30ngkg
 1; P¼0.04).
Number of lung metastases
All except two mice showed LMs. The two mice without LMs had a
small PT (o0.5g) and belonged to the 150ngkg
 1 group and
control group. These mice were excluded from the analyses.
The mean number of LMs in the control group was 1057±244,
compared to 461±99, 1012±241 and 989±228 in the 30, 150 and
500ngkg
 1 group, respectively.
A significant reduction of LMs was detected in the 30ngkg
 1
group compared to the control group (P¼0.016), while in the two
groups treated with higher ML-I doses (150 and 500ngkg
 1), no
significant reduction of the number of LMs was evident
(Figure 1B). The mean number of LMs of mice treated with 150
and 500ng ML-I per kg body weight was significantly higher than
that of the mice treated with low-dose ML-I (30ngkg
 1; P¼0.02).
Size of lung metastases
Lung metastases of the control group had a mean size of 36 cells
(±6.4). Mistletoe lectin-I treatment at 30, 150 and 500ngkg
 1 did
not significantly alter the mean size of the LMs, which was 36±7.9,
37±3.5 and 35.2±6.1 cells per metastasis, respectively (P40.05,
Supplementary Information 1).
Induction of apoptosis in the melanoma cells
Apoptotic rates in the PTs were significantly increased in all three
treatment groups compared to the control group, which showed an
apoptotic rate of 1.68%. Low-dose ML-I treatment (30ng ML-I per
kg body weight) increased apoptosis rates by a factor of 2.6 (4.36%
apoptotic melanoma cells; Po0.0001), while 150 and 500ngkg
 1
increased the number of apoptotic tumour cells by a factor of
1.7 and 1.8, respectively; Po0.01 (Figure 2A). Mistletoe lectin-I
concentrations of 150 and 500ngkg
 1 treatment resulted in
significantly lower apoptosis rates compared to 30ngkg
 1
(Po0.001 and Po0.01, respectively). Apoptosis rates in between
150 and 500ng ML-I per kg did not differ significantly (P40.05).
In the LMs, no significant changes of apoptotic rates through
ML-I treatment were noted (P¼0.09; Figure 2B). Lung metastases
of the control group showed apoptotic rates of 1.8%. Apoptotic
rates in the treated groups ranged from 0.8% (150ngkg
 1 group)
to 2.3% (30ngkg
 1 group).
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Figure 1 (A) Mean tumour weights. Low-dose ML-I (30ng per kg body weight) daily for 19 days significantly reduced the weight of tumour nodules
grown from subcutaneously injected MV3 human melanoma cells, while higher doses had no significant effect. (B) Mean number of lung metastases. Mice
treated with low-dose ML-I (30ng per kg body weight) showed significantly less spontaneous LMs from subcutaneously injected human melanoma cells than
the untreated control mice. The mean number of LMs in the 30ngkg
 1 treatment group was reduced by more than 50%.
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Dendritic cells showed homogenous intensive cytoplasmic as well
as membranous binding of the lectin BSA-I (Figure 3) and were
easy to detect in the PTs and LMs, as the melanoma cells did not
bind this lectin. The DC count in the control group was 35 (±2.6).
Mistletoe lectin-I treatment at doses of 30, 150 and 500ng ML-I per
kg body weight significantly raised the number of infiltrating DCs
(59.5±4.5, Po0.0001; 51. 2±3.9, Po0.05; and 52.7±3.7, Po0.05,
respectively; Figure 4A).
The DC count in the LMs of the control group was 13.9 (±2.5).
In the LMs, the number of infiltrating DCs was not significantly
influenced by ML-I treatment (P40.05, for all ML-I doses;
Figure 4B).
Induction of apoptosis in tumour-infiltrating DCs
The ANOVA analysis of the percentage of apoptotic DCs in the total
number of DCs infiltrating the primary melanomas (Figure 5)
revealed significant differences in the apoptotic rates in between the
different treatment groups (P¼0.001). Low-dose ML-I treatment
(30ng per kg body weight) reduced the apoptotic rate compared to
the control group (15.74% apoptotic DCs vs 18.59%), which,
however, did not reach statistical significance (P40.05). When the
apoptosis rates in between the three ML-I treatment groups were
calculated with the Tukey post-ANOVA test, a significant increase in
apoptotic rates within the DCs in the PTs of the 150 and 500ngkg
 1
groups (21.39 and 22.23% apoptotic DCs) compared to the 30ngkg
 1
group (15.74% apoptotic DCs) became evident (Po0.01; Figure 5).
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Figure 2 (A) Percentage of apoptotic melanoma cells in the PTs. Mistletoe lectin-I treatment at any concentration induced apoptosis in the melanoma
cells of the PTs. (B) Percentage of apoptotic melanoma cells in the LMs. Mistletoe lectin-I treatment had no significant effect on the apoptotic rate in the lung
metastases.
Figure 3 BSA-I lectin histochemistry. Tumour-infiltrating DCs were characterised thanks to their high BSA-I binding capacity; (A) PTs of mice treated with
30ng ML-I per kg body weight showed high numbers of DCs, while PTs of untreated control mice (B) were less infiltrated by DCs.
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Figure 4 Mean number of infiltrating DCs in primary melanomas. Mistletoe lectin-I treatment significantly enhanced the number of DCs infiltrating the
primary melanomas (A), but had no influence on DC number infiltrating the LMs (B).
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When the number of viable DCs was calculated with the Tukey
post-ANOVA test, significantly increased number of PT-infiltrating
viable DCs was found in the 30ngkg
 1 group compared to the
control (Po0.0001) but not any other groups (Figure 6).
Tumour vascularisation
Tumour vessels were highlighted using collagen type IV immuno-
histochemistry (Supplementary Information 2a: PT of a mouse
treated with 500ng ML-I per kg; Supplementary Information 2b: PT
of the control group). The vascular count (mean number of vessels
per 0.5mm
2) in vital tumour mass of melanomas treated with ML-I
at a concentration of 500ngkg
 1 was significantly increased
compared to the control group (42.0±1.7 and 32.4±1.6, respec-
tively; P¼0.001) and to the 30 and 150ngkg
 1 group (34.74±1.3
and 35.1±1.6, respectively, Po0.05; Supplementary Information 2c).
Necrotic tumour area
Primary tumours of all groups showed large necrotic areas
(Supplementary Information 3) of about 35% of the overall
tumour mass. Statistical analyses revealed no significant differ-
ences in the dimension of necrotic tumour area between the
different groups (P40.05; Supplementary Information 4).
Correlation analyses
The results of the correlation analyses are summarised in Table 1.
The rank correlation (Spearman) showed a significant positive
correlation between the weight of the PT and the number of LMs
in the control group and in all three treatment groups. The number
of tumour vessels was neither correlated with the dimension
of necrosis within the PTs nor with the number of LMs (P40.05).
The number of tumour vessels was positively correlated with
the weight of the PT in the control group but not in the treatment
groups.
DISCUSSION
The present study was designed to investigate the potential
antiproliferative and antimetastatic effects of purified ML-I in a
human melanoma scid mouse xenograft model.
Purified ML-I was used, as a strong antiproliferative effect on a
number of human melanoma cell lines, due to the induction of
apoptosis, has already been demonstrated in vitro (Thies et al,
2005). The human melanoma cell line MV3 was used to model a
targeted therapy in vivo, since MV3 cells expressed high numbers
of ML-I-binding sites and proved to be ultrasensitive to ML-I
cytotoxicity in vitro (Thies et al, 2005).
Our previously obtained in vitro results can now be extended to
in vivo, as our results demonstrate a significant antitumorigenic
and an antimetastatic effect of purified ML-I on malignant
melanoma. Purified ML-I administered at 30ng per kg body
weight daily for 19 days reduced the mean tumour weight by 35%
(P¼0.031). The number of LMs was reduced by even 56%
(P¼0.015) compared to the control mice. Both beneficial effects,
antiproliferative and antimetastatic, however, were only achieved
at low-dose ML-I (30ng per kg body weight), but not at higher
doses (150 and 500ngkg
 1). Therefore, counterproductive
mechanisms of ML-I effects at higher doses (150 and 500ng ML-I
per kg) abrogate the significant beneficial ML-I effects exerted at
low-dose treatment (30ngkg
 1).
This significant stronger effect of low-dose ML-I on tumour
growth and spread and reduction or even abrogation of its
beneficial effects at higher doses has already been described in
different tumour entities. Schumacher et al (2000) have shown
similar effects of recombinant ML-I (rML-I) in a human ovarial
carcinoma xenograft scid mouse model. Alike our results, only
low-dose rML-I (30ngkg
 1) significantly reduced tumour growth,
while higher doses (150, 500ngkg
 1) lost this effect. Weber et al
Table 1 Spearman rank correlation analyses
Variables Treatment group rP
TW, LMs Control 0.6 0.005*
30ng/kg 0.8 o0.0001*
150ng/kg 0.7 0.0005*
500ng/kg 0.7 0.002*
VC, TW Control 0.4 0.04*
30ng/kg 0.2 0.3
150ng/kg  0.06 0.4
500ng/kg  0.2 0.2
VC, LMs Control 0.2 0.18
30ng/kg 0.1 0.30
150ng/kg 0.1 0.42
500ng/kg  0.1 0.33
VC, Nec Control  0.1 0.29
30ng/kg 0.3 0.10
150ng/kg  0.02 0.47
500ng/kg 0.1 0.39
LMs¼number of lung metastases; Nec¼dimension of necrosis; TW¼tumour
weight; VC¼vascular count. *Significant correlation.
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Figure 5 Percentage of apoptotic DCs in primary melanomas. Low-dose
ML-I (30ngkg
 1) protected DCs against apoptosis, while doses higher than
30ng per kg body weight significantly induced apoptosis in the DCs
infiltrating the primary melanomas.
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Figure 6 Number of viable DCs. Low-dose ML-I significantly enhanced
the number of viable DCs infiltrating the PTs, whereas higher ML-I
abrogated this effect.
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s, a towards ML-I content standar-
dised mistletoe extract, inhibited lung colonisation of i.v. injected
melanoma cells at a 30ng ML-I per kg body weight equivalent
dosage, while higher doses were less effective. Hence, these results
emphasise the need to answer the question for the mechanisms
underlying dose-dependent differential ML-I effects.
One such mechanism might be found in the immunomodulatory
effect of ML-I. In addition to its cytotoxic effect, ML-I is known to
have a broad influence on the immune system, as increased levels
of interleukins, TNF-a, interferon-g and granulocyte–monocyte
colony-stimulating factor, as well as an increased activity of
macrophages and NK cells have been shown in vitro and in vivo
(Hajto et al, 1989, 1997). These immunostimulatory effects are
exerted at low-dose ML-I (1–10ngml
 1), whereas higher doses
(above 100ngml
 1) abrogate these effect by inducing apoptosis in
the leucocytes (Bu ¨ssing et al, 1997). Hajto et al (2005) reviewed the
effects of ML-I in vitro and in vivo, demonstrating differential
susceptibility of different cell types and even of leucocyte
subpopulations towards ML-I cytotoxicity.
To evaluate the cytotoxic effect of ML-I on malignant melanoma
in vivo, we assessed apoptotic rates of the malignant melanoma
cells, demonstrating a significant direct cytotoxic effect of ML-I on
malignant melanoma cells in the PTs. The strongest cytotoxic effect
was noted at low-dose ML-I (30ngkg
 1), where apoptosis rates were
increase by a factor of 2.6 over the vehicle control (Po0.0001).
Primary tumours in the groups with higher doses also showed
increased apoptosis rates (factor 1.7 (150ngkg
 1) and 1.8
(500ngkg
 1); Po0.01); however, apoptosis rates did not increase
in parallel to increased ML-I concentrations as one would have
expected from our in vitro data (Thies et al,2 0 0 5 ) .A sn os i g n i f i c a n t
reduction in tumour weight was noted in the two groups with higher
ML-I doses, the direct cytotoxic effect of ML-I seems to play only a
minor role in its antitumorigenic effect in vivo. Thus, these results
demonstrate the importance of in vivo models.
To elucidate the significance of immunomodulatory effects of
ML-I on melanoma growth and spread, the number of tumour-
infiltrating DCs was analysed. Mistletoe lectin-I treatment
significantly increased the total number of DCs in the PTs of all
treatment groups. However, DCs express high numbers of ML-I-
binding sites (Thies et al, 2007b), which is not only the prerequisite
for activation by ML-I but also for internalisation of the lectin
followed by apoptosis induction in the DCs (see above). We
therefore analysed apoptosis rates within the DCs in the different
treatment groups, demonstrating that low-dose ML-I (30ngkg
 1)
protected DCs against apoptosis (apoptosis rate reduced by about
16% compared to control), while higher ML-I doses (150 and
500ngkg
 1) significantly increased apoptosis rates in the DCs
(Po0.01). Analysing the number of viable DCs, we could
demonstrate that viable DCs were increased in the 30ng ML-I
per kg group but not in the two groups receiving higher ML-I
doses. These results would attribute the antimelanoma effects of
ML-I at low dose (30ngkg
 1) to the number of infiltrating DCs,
and would suggest that the stimulation of the immune system
plays the prominent role in its antimelanoma effect. Thus, low-
dose ML-I both raised the number of DCs and simultaneously
protected them against apoptosis.
In contrast to the above discussed effects of ML-I on PTs, in the
LMs, neither a significant induction of apoptosis in the melanoma
cells nor an increased number of infiltrating DCs at any ML-I
concentration was evident. Hence, the prominent reduction of
the number of LMs in the group treated with low-dose ML-I
(30ngkg
 1) can neither be attributed to a direct cytotoxic effect on
the tumour cells in the LMs nor to enhanced DC infiltration. As
correlation analyses revealed a highly significant positive correla-
tion between the weight of the PTs and the number of
corresponding LMs in all groups, the significant reduction of
LMs at low-dose ML-I (30ng ML-I per kg) seems to be the
consequence of successful reduction of the PT mass due to ML-I
treatment. Additionally, a cytotoxic effect on circulating melanoma
cells in the bloodstream, which are more prone to apoptosis
induction than cells within the PT (Weber et al, 1998), could have
attributed to the prominent reduction of the number of LMs.
Especially, the reduction of the number of LMs but not of their size
underlines the considerably stronger cytotoxic effect on circulating
tumour cells, while in established metastases cytotoxic effects of
ML-I seem to play a minor role.
As ML-I both induces apoptosis in tumour cells and simulta-
neously enhances the number of PT-infiltrating DCs, adjuvant
ML-I treatment could have important impact in future melanoma
therapy. Upon phagocytosis of apoptotic melanoma cells, DCs
induce a strengthened specific immune response (Shaif-Muthana
et al, 2000). This effect is already used for tumour vaccination
(Ehlken et al, 2004), and melanoma patients vaccinated with
mature DCs showed significant tumour regression (Hersey et al,
2004; Rescigno et al, 2004). Furthermore, the tumour-induced
reduction of DC number and activity in the sentinel lymph node,
which increases the risk for metastasis (Vuylsteke et al, 2004), was
diminished by preoperative local injection of granulocyte–
macrophage colony-stimulating factor, significantly improving
the patient’s prognosis (Vuylsteke et al, 2004). As scid mice lack
T- and B lymphocytes, specific antimelanoma immune response
upon ML-I treatment could not be analysed in our model system.
However, local injection of low-dose ML-I might have similar
beneficial effects as local injection of granulocyte–macrophage
colony-stimulating factor and, furthermore, it would simulta-
neously induce apoptosis in the melanoma cells.
To analyse whether the European ML-I acts as an antiangiogenic
agent, as has been discussed for Korean ML-I (Yoon et al, 1995;
Park et al, 2001), we quantified the number of tumour-infiltrating
vessels. However, no antiangiogenic effect of the European ML-I
could be shown in our model. High-dose ML-I (500ngkg
 1) even
increased the vessel density in the PTs compared to the controls
(P40.001). To elucidate this discrepancy, we analysed whether
hypoxia in the necrotic and subnecrotic tumour area, being a
strong proangiogenic trigger (Moeller et al, 2004), might have
influenced our vascular count data. However, all groups showed
comparable dimension of necrosis within the PTs and no
correlation between diameter of necrosis and tumour vessels was
evident. Thus, in our model no antiangiogenic effect of European
ML-I was evidenced; however, differences in the effects on various
tumour cells between Korean and European ML-I have already
been shown (Yoon et al, 1999). Further correlation analyses
revealed no correlation between vascular density and the number
of LMs, or the weight of the PT, which shows that the period of 20
days of tumour growth and ML-I treatment might be too short to
sufficiently model the complex mechanisms of the effects on
vascularisation. However, the size of the PTs in the control group
limited the duration of the experiment.
ML-I treatment had no negative influence on the vitality,
behaviour and physiological responses, appearance, or food and
water habits of the animals at any dosage, underlining the excellent
tolerance of ML-I treatment. Studies on the quality of life of
tumour patients are in accordance with our findings. Breast cancer
patients treated with ML-I showed elevated b-endorphin levels
(Heiny and Beuth, 1994), which would also be beneficial for
melanoma patients. Furthermore, adjuvant ML-I therapy improved
the tolerance of radio- and chemotherapy for different tumour
entities (Kienle et al, 2003; Bock et al, 2004).
In conclusion, low-dose purified ML-I reduced melanoma
growth and number of metastases in a xenograft model. The
enhancement of DC infiltration and apoptosis induction in the
melanoma cells seem to play the key role for these observed effects.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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